Altering disease progression: The key to successful patient management

BJU International

Volumn 93, Issue SUPPL. 1, 2004, Pages 16-20

  Nordling, J ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANDROGEN; ANDROSTANOLONE; DOXAZOSIN; DUTASTERIDE; FINASTERIDE; PLACEBO; PROSTATE SPECIFIC ANTIGEN; STEROID 5ALPHA REDUCTASE INHIBITOR; TESTOSTERONE;

ALGORITHM; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; ENZYME INHIBITION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE DISEASE; PROSTATE HYPERTROPHY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REVIEW; SCORING SYSTEM; SIDE EFFECT; SYMPTOMATOLOGY; TREATMENT OUTCOME; TREATMENT PLANNING;

ADRENERGIC ALPHA-ANTAGONISTS; DISEASE PROGRESSION; HUMANS; MALE; PRACTICE GUIDELINES; PROSTATIC HYPERPLASIA; TESTOSTERONE 5-ALPHA-REDUCTASE; URINARY RETENTION;

EID: 1642375649     PISSN: 14644096     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2003.04635.x     Document Type: Review

References (30)

1. Berry SJ, Coffey DS, Walsh PC et al. The development of human benign prostatic hyperplasia with age. J Urol 1984; 132: 474-9
2. Roehrborn CG, McConnell JD. Etiology, pathophysiology, epidemiology and natural history of benign prostatic hyperplasia. In Walsh PC, Retik AB, Vaughan ED Jr, Wein AJ eds, Campbell's Urology, Chapt 38. Philadelphia, PA: WB Saunders Company, 2002: 1297-330
3. Girman CJ, Jacobsen SJ, Tsukamoto T et al. Health-related quality of life associated with lower urinary tract symptoms in four countries. Urology 1998; 51: 428-36
4. de la Rosette JJ, Alivizatos G, Madersbacher S et al. for the European Association of Urology. EAU Guidelines on benign prostatic hyperplasia (BPH). Eur Urol 2001; 40: 256-63
5. AUA BPH Guideline Update Panel. The Management of BPH, 2003. 〈http:// www.auanet.org/timssnet/products/ guidelines/bph_management. cfm〉.
6. Boyle P. Some remarks on the epidemiology of acute urinary retention. Arch Ital Urol Nefrol Androl 1998; 70: 77-82
7. Glynn RJ, Campion EW, Bouchard GR et al. The development of benign prostatic hyperplasia among volunteers in the Normative Aging Study. Am J Epidemiol 1985; 121: 78-90
8. Lee C, Kozlowski JM, Grayhack JT. Aetiology of benign prostatic hyperplasia. Urol Clin N Am 1995; 22: 237-46
9. Cunha GR, Donjacour AA, Cooke PS, et al. The endocrinology and developmental biology of the prostate. Endocr Rev 1987; 8: 338-62
10. Jacobsen SJ, Girman CJ, Guess HA et al. Natural history of prostatism: longitudinal changes in voiding symptoms in community dwelling men. J Urol 1996; 155: 595-600
11. McConnell JD, Bruskewitz R, Walsh P et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. N Engl J Med 1998; 338: 557-63
12. Emberton M, Andriole GL, de la Rosette JJ et al. Benign prostatic hyperplasia: a progressive disease of aging men. Urology 2003; 61: 267-73
13. Roberts RO, Jacobsen SJ, Jacobsen DJ et al. Longitudinal changes in peak urinary flow rates in a community-based cohort J Urol 2000; 163: 107-13
14. Rhodes T, Girman CJ, Jacobsen SJ, Roberts RO, Guess HA, Lieber MM. Longitudinal prostate growth rates during 5 years in randomly selected community men 40-79 years old. J Urol 1999; 161: 1174-9
15. Rhodes T, Girman CJ, Jacobsen DJ et al. Longitudinal prostate volume in a community-based sample: 7 year follow-up in the Olmsted County study of urinary symptoms and health status among men. J Urol 2000; 163: 249
16. Jacobsen CJ, Jacobsen DJ, Girman CJ et al. Natural history of prostatism: risk factors for acute urinary retention. J Urol 1997; 158: 481-7
17. Girman CJ, Jacobsen SJ, Rhodes T, Guess HA, Roberts RO, Lieber MM. Association of health-related quality of life and benign prostatic enlargement. Eur Urol 1999; 35: 277-84
18. O'Leary MP, Roehrborn C, Andriole G, Nickel C, Boyle P, Hofner K. Improvements in benign prostatic hyperplasia-specific quality of life with dutasteride, the novel dual 5α-reductase inhibitor. BJU Int 2003; 92: 262-6
19. Roehrborn CG, Boyle P, Nickel JC, Hoefner K, Andriole G on behalf of the ARIA3001, ARIA3002 and ARIA3003 Study Investigators. Efficacy and safety of a dual inhibitor of 5 alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology 2002; 60: 434-41
20. Boyle P, Gould AL, Roehrborn CG. Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: meta-analysis of randomized clinical trials. Urology 1996; 48: 398-405
21. Roehrborn CG, Boyle P, Bergner D et al. for the PLESS Study Group. Serum prostate-specific antigen and prostate volume predict long-term changes in symptoms and flow rate: results of a four-year, randomized trial comparing finasteride versus placebo. Urology 1999; 54: 662-9
22. Roehrborn CG, McConnell JD, Lieber M et al. Serum prostate-specific antigen concentration is a powerful predictor of acute urinary retention and need for surgery in men with clinical benign prostatic hyperplasia. PLESS Study Group. Urology 1999; 53: 473-80
23. Borth CS, Beiko DT, Nickel JC. Impact of medical therapy on transurethral resection of the prostate: a decade of change. Urology 2001; 57: 1082-5
24. Bruskewitz R, Girman CJ, Fowler J et al. Effect of finasteride on bother and other health-related quality of life aspects associated with benign prostatic hyperplasia. Urology 1999; 54: 670-8
25. Vaughan D, Imperato-McGinley J, McConnell J et al. Long-term (7-8-year) experience with finasteride in men with benign prostatic hyperplasia. Urology 2002; 60: 1040-4
26. Ekman P and the Scandinavian Finasteride Study Group. Maximum efficacy of finasteride is obtained within 6 months and maintained over 6 years: follow-up of the Scandinavian Open-Extension Study. Eur Urol 1998; 33: 312-7
27. Lam JS, Romas NA, Lowe FC. Long-term treatment with finasteride in men with symptomatic benign prostatic hyperplasia: 10-year follow-up. Urology 2003; 61: 354-8
28. McConnell JD, Roehrborn CG, Bautista OM et al. The long-term effect of doxazosin, finasteride and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003; 349: 2387-98
29. Bautista OM, Kusek JW, Nyberg LM et al. Study design of the Medical Therapy of Prostatic Symptoms (MTOPS) trial. Control Clin Trial 2003; 24: 224-43
30. Barkin J, Guimaraes M, Jacobi G, Pushkar D, Taylor S, van Vierssen Trip OB on behalf of the SMART-1 Investigator Group. Alpha-blocker therapy can be withdrawn in the majority of men following initial combination therapy with the dual 5α-reductase inhibitor dutasteride. Eur Urol 2003; 44: 461-6